About
Contact & Profiles
A5103180231
Research Areas
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Viral Infectious Diseases and Gene Expression in Insects
- Protein purification and stability
- SARS-CoV-2 and COVID-19 Research
Merck & Co., Inc., Rahway, NJ, USA (United States)
2020
Messenger RNA (mRNA) vaccines have emerged as a flexible platform for vaccine development. The evolution of lipid nanoparticles effective delivery vehicles modified mRNA encoding antigens was demonstrated by the response to COVID-19 pandemic. ability rapidly develop SARS-CoV-2 from spike protein genome, and then manufacture multibillions doses per year an extraordinary achievement milestone. Further development application this additional pathogens is clearly interest. This comes with...
10.3390/vaccines11071224
article
EN
cc-by
Vaccines
2023-07-10
10.1208/s12248-020-00521-5
article
EN
The AAPS Journal
2020-11-01
Coming Soon ...